Retrospective analysis reveals eosinopenia and high IgE levels predict omalizumab drug survival outcomes.
Our study aimed to evaluate drug survival after omalizumab treatment by using biomarkers. Our findings suggest that eosinopenia/basopenia may predict shorter omalizumab drug survival, and high baseline total IgE levels are associated with higher relapse rates after treatment cessation in CSU patients.
No takes yet. Share an insight, caveat, or question.
Aydoğdu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: